Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verona Pharma PLC VRNA

Healthcare
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual... see more

Recent & Breaking News (NDAQ:VRNA)

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

GlobeNewswire 3 days ago

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire 10 days ago

Andrew Fisher Joins Verona Pharma as General Counsel

GlobeNewswire March 4, 2024

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire February 29, 2024

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

GlobeNewswire February 15, 2024

Michael Austwick Joins Verona Pharma as Non-Executive Director

GlobeNewswire February 1, 2024

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

GlobeNewswire January 2, 2024

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

GlobeNewswire November 17, 2023

Verona Pharma Announces November 2023 Investor Conference Participation

GlobeNewswire November 8, 2023

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 2, 2023

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

GlobeNewswire October 19, 2023

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

GlobeNewswire October 6, 2023

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

GlobeNewswire October 3, 2023

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

GlobeNewswire September 11, 2023

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

GlobeNewswire September 6, 2023

Christina Ackermann Joins Verona Pharma as Non-Executive Director

GlobeNewswire August 31, 2023

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 3, 2023

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

GlobeNewswire July 26, 2023

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

GlobeNewswire July 20, 2023